As the only FDA cleared medical device capable of automatically detecting and quantifying atrophy in the human brain, NeuroQuant brings sophisticated, accurate, and fully automated MRI post-processing capabilities to the physician’s desktop or mobile device.

It provides neurologists, radiologists, and clinical researchers with a convenient and cost-effective means to quantify atrophy of brain structures to help diagnose a variety of brain disorders, including conditions such as Alzheimer’s disease, epilepsy and traumatic brain injury.

CorTechs Labs CEO Guri Stark said the company is pleased to expand its relationship with Invivo.

"With great expertise and presence in advanced clinical solutions for MRI, Invivo has been a terrific partner and has demonstrated exceptional growth with our NeuroQuant product in the US," Stark added.

"We look forward to partnering with Invivo to continue NeuroQuant’s growth momentum and establishing our vision to have NeuroQuant® become the standard test for all brain disorders, including Alzheimer’s disease, epilepsy and traumatic brain injury."